Study details
Enrolling now
Ketamine Trial for Suicidal Patients
Lindsay Maguire, MD
NCT IDNCT06085937ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
50
Study length
about 2 years
Ages
18–65
Locations
2 sites in KS
About this study
This trial is testing if low-dose intravenous ketamine can be safely used in the Emergency Department to help people with suicidal thoughts. The goal is to determine whether this treatment is safe and feasible.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ketamine
PhasePhase 1
DrugKetamine
Primary goalIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low7%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia)
Endpoints
Primary: Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Secondary: Hospital Length of Stay
Body systems
Psychiatry / Mental Health